System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Julie Charles is an expert in Dermatology at Centre Hospitalier Universitaire de Grenoble (France). As of October 2026, ScienceLeadR ranks Julie Charles in the top 1% of experts worldwide for Skin Neoplasms and Melanoma. Julie Charles has authored 108 publications, the most recent in 2026, and is an investigator in 15 clinical trials, 6 of them ongoing. SLR score: 567 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Julie Charles Centre Hospitalier Universitaire de Grenoble France
567 ScienceLeadR Reputation 567

Unlock

Register Login
Network Map

Dermatology

Subspecialties: Oncology - Immunology - Radiotherapy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2005 - 2026
Source: PubMed

Centre Hospitalier Universitaire de Grenoble

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 108

Citations

Citations: 7 635 1st author: 14 Last author: 8 Unique author: 0

Main journals

Ann Dermatol Venereol 16
J Clin Oncol 7
Front Immunol 5
Cancer Res 4
J Am Acad Dermatol 4

Best Journals

J Clin Oncol 5
Ann Oncol 1
N Engl J Med 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single-Arm Phase II Study.
PMID 42791653 — cells, merkel cells, somatostatin, neoplasms, therapeutics, dermatology, carcinoma, merkel cell		Cancer Med20260
Metabolic Profiling of Circulating and Tumour-Infiltrating T Cells Uncovers Bioenergetic Checkpoints Linked With Immune and Clinical Skewing in Melanoma Patients.
PMID 42552605 — cells, melanoma, sterols, metabolomics		Immunology20260
Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS).
PMID 42372635 — melanoma, cohort studies, therapeutics		Eur J Cancer20260
IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma.
PMID 42025759 — cells, vaccines, progression-free survival, melanoma, neoplasms, drug-related side effects and adverse reactions, cancer vaccines		Ann Oncol Top journal20260
Theranostic magnetic hydrogels for treatment, recurrence prevention, tumour modelling and emerging applications in breast cancer management: A review.
PMID 41945987 — hydrogels, breast neoplasms, nanoparticles, pharmaceutical preparations, hyperthermia, neoplasms, multiple chronic conditions, breast, therapeutics		Int J Biol Macromol20261

Clinical Studies 15

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 5

By phase:

Phase 2 6
N/A 5
Phase 3 2
Phase 1 1
Phase 2/Phase 3 1

By status:

Completed 7
Recruiting 5
Active not recruiting 1
Not yet recruiting 1
Terminated 1

By type:

Interventional 12
Observational 3

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 0
multicentric5to9 1
multicentricup10 10

Main Topics

Ongoing Clinical Trials

6 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Phase 3 Multicenter Randomized Double blind Placebo controlled and Deucravacitinib Active Comparator controlled Study to Evaluate the Efficacy and Safety of JNJ 77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
2023-505121-14-00 — safety, therapeutics, psoriasis		Phase 3Active not recruiting2024
Influence of a High fiber Diet on the Microbiota and the Response to Immunotherapy in Patients Treated for Melanoma
NCT07437300 — melanoma, diet, immunotherapy, therapeutics, microbiota		N/ANot yet recruiting2026
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First Line Therapy in Patients With Advanced Melanoma
NCT06697301 — toll-like receptors, safety, melanoma, neoplasms, neoplasm metastasis, therapeutics, toll-like receptor 7		Phase 2/Phase 3Recruiting2025
Profiling of Circulating Immune Cells to Uncover Response Signatures to Anti PD1 Immunotherapy in Melanoma Patients
NCT06154668 — cells, melanoma, immunotherapy, therapeutics		N/ARecruiting2024
Generation of an Artificial Intelligence Algorithm Based on the Analysis of Melanoma Peri scar Dermatoheliosis as a Predictive Factor of Response to Anti PD 1
NCT05856565 — skin, intelligence, cicatrix, melanoma, neoplasms, algorithms, immunotherapy, photography, therapeutics, artificial intelligence		N/ARecruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS